Pfizer has partnered with Beam Therapeutics to develop messenger RNA (mRNA)-based therapies for rare genetic diseases — a move to expand its portfolio of mRNA technology used to produce its landmark COVID-19 vaccine.
Source: Drug Industry Daily
Pfizer has partnered with Beam Therapeutics to develop messenger RNA (mRNA)-based therapies for rare genetic diseases — a move to expand its portfolio of mRNA technology used to produce its landmark COVID-19 vaccine.
Source: Drug Industry Daily